Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of diacerein 1% ointment in epidermolysis bullosa simplex
2017-003757-41Phase 2Completed
- Sponsor
- Castle Creek Biosciences
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of diacerein in epidermolysis bullosa simplex (EBS), epidermolysis bullosa (EB), sponsored by Castle Creek Biosciences. Started Nov 2017; status: completed.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2017-003757-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003757-41.